We are in the midst of a revolution in cancer care. Cancer immunotherapies are proving transformational for many patients around the world. By harnessing the power of our own immune systems, we have the potential to fight certain cancers more effectively than ever before.
But while use of certain cancer immunotherapies can result in profound clinical benefit for some patients, many individuals with cancer do not respond to the currently available therapies in this important new class of medicine. In one study, roughly only about 20-40 percent of patients with cancer respond to immunotherapies1, highlighting the importance of giving oncologists access to new and accurate ways to identify those individuals who will respond to these treatments. Providing oncologists with this ability could save significant time and cost, while at the same time ensuring that cancer patients have access to the most clinically appropriate therapies.
All of this is taking place in the context of an explosion in the advancement and development of targeted therapies that zero in on specific features of the disease, like genomic mutations. In fact, there are hundreds of targeted compounds in clinical development today, targeting almost an equal number of genomic alterations. New clinical trials to test these targeted therapies and combinations are constantly starting. It’s nearly impossible to keep up.
At Foundation Medicine, we believe physicians should have access to as many clinically relevant biomarkers as possible to predict responses to this full range of therapies, in a single, comprehensive test.
In a rapidly evolving treatment landscape, we believe in providing oncologists with the most current, comprehensive information and resources available to help them identify the best treatment approach for their patients.
FoundationOne® and FoundationOne® Heme products now include tumor mutational burden (TMB), a new, quantitative genomic biomarker known to predict responses to certain cancer immunotherapies, such as checkpoint inhibitors.
FoundationOne and FoundationOne Heme were already able to simultaneously detect all clinically relevant classes of genomic alterations. We believe that our reports now uniquely provide oncologists with an even broader range of the molecular information to guide therapeutic decisions for targeted therapies, clinical trials, as well as cancer immunotherapies. We’re bringing the power of the most advanced genomic technologies around the world, right into your community clinic.
This power was demonstrated recently at the American Society of Clinical Oncology (ASCO) annual meeting, where new data continued to validate the ability of TMB to predict a greater likelihood of response and longer response duration to cancer immunotherapies across a wide range of tumor types. Based on data presented at ASCO, we now know that TMB can predict responses to FDA-approved anti-PDL1 and anti-PD1 cancer immunotherapies in bladder cancer, breast cancer, lung cancer and melanoma, as well as other advanced cancers.
The current diagnostic landscape is nearly as complicated as the treatment landscape. Oncologists need to decide which tests to order, how to organize all of the individual reports, and how to synthesize and understand all of the information. Additionally, the need for multiple tissue samples can be challenging, or impossible in previously treated patients with advanced cancers.
The FoundationOne and FoundationOne Heme all-in-one reports now show TMB status alongside our existing comprehensive genomic profiling of all genes known to be somatically altered in cancer, all based on testing a single sample. With the addition of TMB, this single report can now help guide treatment decisions for targeted therapies, referral into clinical trials, and cancer immunotherapies. This biomarker testing is combined with a full suite of patient-centric resources, including our database of nearly 90,000 real-world patient cases, making it even easier for healthcare providers to find the right solution for each patient.
At Foundation Medicine, we are committed to the next chapter in precision medicine. This starts by giving doctors and patients the information they need to predict better.